Studying Safety & Efficacy of Immune Checkpoint Inhibitors in Relapsed SCLC
While immune checkpoint inhibitors have been approved for treating small-cell lung cancer (SCLC), the efficacy and safety profile of immune checkpoint inhibitors for relapsed SCLC is the subject of ongoing investigation, including a study published in the Journal of Clinical Pharmacy and Therapeutics. Read more.

Lung Cancer–Associated Fibroblasts May Be Instrumental in Personalized Treatments
According to findings from a recently published study in the journal Cancer Cell led by researchers at Massachusetts General Hospital, there are three subtypes of cancer-associated fibroblasts, which could guide the design of personalized treatment for lung cancer patients. Rear more.

FDA Approves Atezolizumab for Adjuvant Treatment of Stage II-IIIA NSCLC
The FDA recently announced the approval of the monoclonal antibody atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥1% of tumor cells, as determined by an FDA-approved test. Read more.